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Hearing impairment (HI) is prevalent, is modifiable, and has been associated with cognitive decline. We tested
the hypothesis that audiometric HI measured in 2013 is associated with poorer cognitive function in 253 men and
women from Washington County, Maryland (mean age = 76.9 years) in a pilot study carried out within the Athero-
sclerosis Risk in Communities Neurocognitive Study. Three cognitive tests were administered in 1990–1992, 1996–
1998, and 2013, and a full neuropsychological battery was administered in 2013. Multivariable-adjusted differences
in standardized cognitive scores (cross-sectional analysis) and trajectories of 20-year change (longitudinal analy-
sis) were modeled using linear regression and generalized estimating equations, respectively. Hearing thresholds
for pure tone frequencies of 0.5–4 kHz were averaged to obtain a pure tone average in the better-hearing ear. Hear-
ing was categorized as follows: ≤25 dB, no HI; 26–40 dB, mild HI; and >40 dB, moderate/severe HI. Comparing
participants with moderate/severe HI to participants with no HI, 20-year rates of decline in memory and global func-
tion differed by −0.47 standard deviations (P = 0.02) and −0.29 standard deviations (P = 0.02), respectively. Esti-
mated declines were greatest in participants who did not wear a hearing aid. These findings add to the limited
literature on cognitive impairments associated with HI, and they support future research on whether HI treatment
may reduce risk of cognitive decline.
aging; cognition; cognitive decline; hearing impairment; memory; perbycussis
Abbreviations: ARIC, Atherosclerosis Risk in Communities; CES-D, Center for Epidemiologic Studies Depression Scale; CI,
confidence interval; DSST, Digit Symbol Substitution Test; DWRT, DelayedWordRecall Test; HI, hearing impairment; SD, standard
deviation.
Recent epidemiologic studies have indicated that hearing
impairment (HI) may be a risk factor for cognitive decline
(1–3). HI is highly prevalent in older adults and may be ame-
nable to rehabilitative interventions (4, 5).
The association between hearing loss and cognitive impair-
ment could be explained if both conditions are sequelae of an
underlying pathology (e.g., vascular disease, inflammation).
Alternatively, mechanistic hypotheses have been proposed
that argue for a causal association between HI and cognitive
decline, including increased social isolation and loneliness, in-
creased cognitive load, and changes in brain structure (6).
In prior studies, audiometric HI has been associated cross-
sectionally with test-specific cognitive performance in several
cognitive domains (memory, executive function, and global
function) in older adults (1, 2) and in a longitudinal analysis
with faster rates of decline in global function and executive at-
tention over 6 years of follow-up (3). Data on the use of hear-
ing aids in these studies have been limited.
We used data from a pilot study carried out in a subset of
participants from the Atherosclerosis Risk in Communities
(ARIC) Study to test the hypothesis that, compared with partic-
ipants without HI, participants with HI in older age have poorer
cognitive performance as measured by multiple cognitive tests,
both cross-sectionally at the timewhen hearing ismeasured and
longitudinally, with a faster rate of 20-year change in cognitive
function measured from midlife to older age.
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The effect of correcting HI on cognitive decline is un-
known but is important for public health efforts designed
to prevent cognitive decline in older adults. We hypothesized
that, among participants with HI (i.e., among participants
who would potentially benefit from HI correction), partici-
pants who use hearing aids have slower rates of cognitive de-
cline than participants with HI who do not use hearing aids.
Therefore, we repeated the analyses restricting the data to
only those participants with moderate or severe HI in order




The ARIC Study is a population-based prospective cohort
study of 15,792 men and women aged 45–64 years recruited
in 1987–1989 from 4 US communities (Washington County,
Maryland; Forsyth County, North Carolina; Jackson, Missis-
sippi; andMinneapolis,Minnesota). ARIC participants returned
for a fifth ARIC visit in 2011–2013 (the ARIC Neurocognitive
Study). A pilot study on hearing was initiated at the Washing-
ton County field site in 2013, and audiometric testing was of-
fered to 307 ARIC participants at their regularly scheduled
ARIC visit. Six declined participation, and 46 did not complete
the examination (45 of them because of compacted cerumen in
one or both ears). Since only 2 participants were nonwhite,
analysis was restricted to self-reported whites, resulting in an
analytical sample of 253. Compared with other ARIC 2011–
2013 participants, participants in the hearing pilot study were
older (77.1 (standard deviation (SD), 5.4) years vs. 75.7 (SD,
5.3) years; P < 0.01) and more likely to have a high school ed-
ucation or less (60% vs. 46%; P < 0.01). Participants in the
pilot study who were included in our analysis scored higher
on the Wide Range Achievement Test (45.5 (SD, 6.1) vs.
42.9 (SD, 8.0);P = 0.04) and trended toward a lower proportion
with less education (60% vs. 67%;P = 0.31). Informed consent
was obtained from all participants at each study visit.
Cognitive outcomes
Cross-sectional measures. A comprehensive neuropsy-
chological battery was administered in 2013. Standardized
test scores were used to create summary cognitive-domain
scores in the following domains: 1)memory—Delayed Word
Recall Test (DWRT) (7), Incidental Learning Test (8), and
LogicalMemory Test I and II (9); 2) language—Word Fluency
Test (10), Animals Naming Test (11), and Boston Naming Test
(12); and 3) processing speed/attention—Digit Symbol Sub-
stitution Test (DSST) (13), Digit Span Backwards Test (13),
and Trail Making Test Parts A and B (14, 15). Scores on the
Trail Making Test Parts A and B were transformed to the
natural log values to account for nonnormality. All test scores
were standardized to z scores, and arithmetic signs were
changed for the Trail Making tests so that higher scores indi-
cated better function for all tests. All test-specific z scores
were then averaged within each domain to yield a domain-
specific score. A global cross-sectional composite score was
created byaveraging the 3 domain-specific z scores. In order to
facilitate comparisons, the global composite score and each
domain score were then scaled so that 1 unit equaled 1 SD of
that score.
Most of these cognitive tests included both auditory and
written stimuli. Two tests that administer only auditory stim-
uli, the Logical Memory Test and the Digit Span Backwards
Test, were excluded from the domain-specific summary scores
in sensitivity analyses.
Longitudinal measures. Three neuropsychological tests
representing the different cognitive domains—memory
(DWRT), language (Word Fluency Test), and processing speed/
attention (DSST)—were administered 3 times, in 1990–1992,
1996–1998, and 2013. For longitudinal analyses, the z scores
for these tests at each testing occasion were scaled to their
mean and the SD on first testing at baseline (1990–1992). Con-
sistent with previous studies in this cohort (16, 17), the sum of
the 3 test-specific z scores was used to create a global longitu-
dinal composite score that was then scaled to the baseline SD
of that global score.
Hearing assessment
Pure tone air conduction audiometry was conducted in a
sound-treated booth in 2013.Air conduction thresholds in each
ear were obtained at standard octaves from 0.5 kHz to 8 kHz
by trained technicians using insert earphones (EARTone
3a; 3M, St. Paul, Minnesota) and an Interacoustics AD629
audiometer (Interacoustics A/S, Assens, Denmark). All thresh-
olds were measured in decibels of hearing level. For each
participant, the threshold levels for the pure tone frequen-
cies of 0.5 kHz, 1 kHz, 2 kHz, and 4 kHz in the better-
hearing ear were averaged to obtain a pure tone average in
accordance with the World Health Organization (18). We
categorized pure tone average according to clinically de-
fined cutpoints for HI (normal: ≤25 dB; mild: 26–40 dB;
moderate/severe: >40 dB); because only 5 participants had
severe HI (>70 dB), moderate and severe HI were combined
to create 1 category.
Hearing aid use was defined as self-reported use of a hear-
ing aid in either ear during the previous month.
Other independent variables
Demographic information was collected in 1987–1989, in-
cluding age (years), sex, and education (highest grade or year
of school completed). Education was categorized for analysis
as ≤12 years and >12 years.
Self-reported information on current and past cigarette
smoking was collected at each study visit and coded as ever
or never for analysis. Hypertension (19) was considered pres-
ent if diastolic blood pressure was greater than or equal to
90 mm Hg, systolic blood pressure was greater than or equal
to 140 mm Hg, or the participant took hypertensive medica-
tion. Diabetes (19) was defined as fasting blood glucose level
≥126 mg/dL, nonfasting blood glucose level ≥200 mg/dL,
or self-reported physician’s diagnosis of diabetes or use of
medication for diabetes.
Depressive symptoms were measured in 1990–1992 using 7
items that relate to depression from the 21-item Maastricht
Questionnaire, which assesses vital exhaustion (20). Responses
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to these items (0 = no, 1 = don’t know, and 2 = yes) were
summed to yield a possible score ranging from 0 to 14, with
higher scores indicating higher levels of depressive symp-
toms. Depressive symptomatology in 2013 was measured
using the 11-item Center for Epidemiologic Studies Depres-
sion Scale (CES-D) (21). Possible 11-item CES-D scores
range from 0 to 22, with an observed range in this sample
of 0–15; higher scores indicate greater depressive symptoma-
tology. Given the absence of clinical depression (CES-D
scores were less than 16 for all participants) and because
the distribution of CES-D scores in this sample was highly
skewed, for analysis CES-D scores were categorized at the
median value of the distribution (≤3 vs. ≥4).
Statistical analysis
Multivariable linear regression was used to estimate the av-
erage cross-sectional difference in cognitive test performance
in 2013, comparing persons with and without HI.
For the longitudinal analysis, in order to account for the cor-
relation between repeated cognitive measures in an individual
over time, generalized estimating equations (22) with an un-
structured correlation matrix and robust variance were used
to estimate the difference in the estimated average trajectories
of cognitive change over time (1990–2013) according to HI
status as measured in 2013. An interaction term for the inter-
action between HI and time was included in the models in
order to test whether rates of cognitive change over time dif-
fered by hearing status. Time since baseline was used as the
time scale. A 2-piece linear spline with a knot at year 6 was
included in the model in order to allow for differential rates
of cognitive change before and after year 6. Year 6 was chosen
a priori as the knot for the spline on the basis of theARIC study
design: 6 years was the mean follow-up time between baseline
and the second round of cognitive testing (1996–1998), after
which there was a subsequent 16-year gap until cognitive test-
ing was performed in 2013. Model fit was good, as assessed
using residual plots, the Bayesian Information Criterion, and
the Akaike Information Criterion.
Models were adjusted for demographic and disease covari-
ates that were measured in 1987–1989, including education
and sex. Time-varying covariates, including age, smoking sta-
tus, hypertension, and diabetes, were measured at baseline for
the longitudinal analysis or in 2013 for the cross-sectional anal-
ysis. All analyses also adjusted for scores on the Wide Range
Achievement Test, a measure of premorbid intelligence, ad-
ministered in 2013. Agewas modeled using both linear (years)
and quadratic (years2) components. Because depression could
be a possible mediator of the relationship between HI and cog-
nitive performance, we did not adjust for depression in our pri-
mary model. In a sensitivity analysis, we repeated the analyses
with adjustment for depressive symptoms.
To evaluate the association of hearing aid use with cogni-
tive performance, we repeated the analyses after restricting
the data to persons with moderate or severe HI.
RESULTS
Of 253 participants, 73 (29%) had no HI, 95 (37%) had
mild HI, and 85 (34%) had moderate or severe HI. Mean age
at the time of the hearing assessment was 76.9 (SD, 5.4)
years, and 58.9% of participants had a high school education
or less. On average, participants with moderate/severe HI
were older (79.4 years) and more likely to be male (54%) and
to have hypertension at baseline (33%) than participants with
mild or no HI (Table 1).
Mean test scores across categories of HI differed in 2013
for some (but not all) tests of memory (DWRT, Inciden-
tal Learning Test), language (Animal Naming Test, Boston
Naming Test), and processing speed/executive function
(DSST). DWRT and DSST scores also differed at baseline.
A dose-response relationship between HI category and per-
formance on each of these tests was suggested; mean test
scores were poorest for participants with moderate/severe
HI and best for participants with no HI. We did not observe
a difference in mean test scores by HI category in tests that
used only auditory stimuli (the Logical Memory Test and
the Digit Span Backwards Test), which may reflect adminis-
tration of all tests in a quiet room by technicians trained to
work with older adults (Table 2).
Compared with participants with no HI, participants with
mild HI showed poorer concurrent memory domain perform-
ance (−0.35 SDs, 95% confidence interval (CI): −0.62,
−0.07; P = 0.01) in cross-sectional analysis (see model 1 in
Web Table 1, available at http://aje.oxfordjournals.org/).
When cognitive tests that include only auditory stimuli (Log-
ical Memory Test and Digit Span Backwards Test) were
excluded from the cognitive domain summary scores, we ob-
served significant differences in memory performance for
both moderate/severe HI and mild HI: −0.39 SDs (95% CI:
−0.70, −0.07) and −0.37 SDs (95% CI: −0.65, −0.08), re-
spectively (Web Table 1, model 3). Inferences did not change
after adjustment for depressive symptoms (Web Table 1,
models 2 and 4).
Observed mean scores by HI status on each of the 3 cogni-
tive testing occasions are presented in Figure 1. There is the
suggestion of a dose-response relationship between HI cate-
gory and cognitive decline. After adjustment for demographic
and disease covariates, on average, cognitive performance in
all domains declined for all 3 HI groups during the approxi-
mately 20 years of follow-up (Table 3, Figure 2). Compared
with participants with noHI, participantswithmoderate/severe
HI declined at a faster rate on the DWRT and the global com-
posite score; comparing the 2 groups, the average difference in
the rate of 20-year decline was −0.47 SDs (95% CI:
−0.86, −0.08) for the DWRT and −0.29 SDs (95% CI:
−0.54, −0.05) for the global composite score. Further adjust-
ment for depressive symptoms did not change the estimates
(Web Table 2).
Among the 85 participants with moderate/severe HI, 51%
(n = 43) reported using a hearing aid (Table 1). Compared
with hearing aid users, nonusers were more likely to have hy-
pertension (45% vs. 21% at baseline (P = 0.02) and 83% vs.
70% in 2013 (P = 0.14)) and diabetes (14% vs. 7% at baseline
(P = 0.31) and 48% vs. 33% in 2013 (P = 0.16)). Duration of
hearing aid use varied across participants and ranged from less
than 1 year to 48 years (Table 1). In multivariable-adjusted
analyses among participants with moderate/severe HI, not
using a hearing aid was associated with poorer cross-sectional
performance in memory (−0.74 SDs, 95% CI: −1.16, −0.32),
682 Deal et al.
Am J Epidemiol. 2015;181(9):680–690






(n = 73) P Valueb








No. % No. % No. % No. % No. % No. %
Age, yearsc
1990–1992 (baseline) 56.6 (5.3) 59.1 (5.4) 59.1 (5.4) 59.3 (5.0) 56.4 (4.9) 53.8 (4.0) 0.0001
2013 76.9 (5.4) 79.4 (5.7) 79.4 (5.7) 79.8 (6.0) 76.8 (4.9) 74.0 (4.2) 0.0001
High school education or lessd 149 58.9 51 60.0 27 64.3 24 55.8 56 59.0 42 57.5 0.952
Male sexd 99 39.1 46 54.1 20 47.6 26 60.5 37 39.0 16 21.9 <0.0001
Ever smoker
1990–1992 (baseline) 112 44.3 41 48.2 17 40.5 24 55.8 41 43.2 30 41.1 0.642
2013 122 48.2 44 51.8 19 45.2 25 58.1 45 47.4 33 45.2 0.697
Diabetes
1990–1992 (baseline) 19 7.5 9 10.6 6 14.3 3 7.0 7 7.4 3 4.1 0.305
2013 86 34.0 34 40.0 20 47.6 14 32.6 32 33.7 20 27.4 0.248
Hypertension
1990–1992 (baseline) 59 23.3 28 32.9 19 45.2 9 20.9 18 19.0 13 17.8 0.036
2013 182 71.9 65 76.5 35 83.3 30 69.8 64 67.4 53 72.6 0.394
Depressive symptomse,f
1990–1992 (baseline) 2 (0–4) 2 (0–4) 2 (0–4) 2 (0–4) 2 (0–4) 2 (0–4) 0.792
2013 3 (1–5) 3 (1–6) 3.5 (1–5) 3 (1–7) 2 (1–5) 3 (1–5) 0.295
Wide Range Achievement Testc,g,h 45.5 (6.1) 44.4 (6.0) 44.7 (5.7) 44.2 (6.4) 46.2 (5.9) 45.7 (6.2) 0.137
Hearing level (pure tone average), dBc,h 35.2 (15.2) 52.1 (9.6) 49.6 (8.7) 54.5 (9.8) 33.2 (4.1) 18.1 (6.3)
Hearing aid useh,i 52 20.6 43 50.6 0 0.0 43 100.0 6 6.3 3 4.1 <0.0001
Duration of hearing aid use, yearsf,h,j 4 (2–10) 3 (2–4) 7 (1–12) 0.808
Abbreviation: HI, hearing impairment.
a HI was defined as none (≤25 dB), mild (26–40 dB), or moderate/severe (>40 dB).
b For continuous variables, P value from 1-way analysis of variance or a Kruskall-Wallis test comparing mean/median cognitive test scores across categories of HI (moderate/severe, mild,
none); for categorical variables, P value from Pearson’s χ2 test.
c Values are expressed as mean (standard deviation).
d Measured in 1987–1989.
e Score was based on 7 questions from the 21-item Maastricht Questionnaire, administered in 1990–1992 (possible range, 0–14), and the 11-item Center for Epidemiologic Studies
Depression Scale, administered in 2013 (possible range, 0–22).
f Values are expressed as median and interquartile range (25th–75th percentiles).
g A measure of premorbid intelligence.
h Measured in 2013 only.
i Defined as self-reported hearing aid use in either ear during the previous month.
j The ranges of duration of hearing aid use were 0.5–48 years, 1–15 years, and 1–12 years for participants with moderate/severe HI (n = 43), mild HI (n = 6), and no HI (n = 3) who reported



















































language (−0.78 SDs, 95% CI: −1.20, −0.36), and global
function (−0.64, 95% CI: −1.03, −0.24) (Web Table 3). Esti-
mated average 20-year changes were greater for hearing aid
nonusers than for hearing aid users in memory (−0.95 SDs,
95% CI: −1.53, −0.38) and global function (−0.48 SDs,
95% CI: −0.83, −0.14) (Table 4).
DISCUSSION
In this pilot study, carried out among 253 white ARIC
Neurocognitive Study participants fromWashington County,
Maryland (mean age = 77 years), our results demonstrated
that moderate/severe HI measured in late life was associated
with poorer concurrent memory performance and with a
faster rate of prior 20-year decline in both memory and global
cognitive function. Although, on average, all participants
with moderate/severe HI declined in all 3 domains, the great-
est decline was estimated for participants who reported not
using a hearing aid. The estimated 20-year rate of decline
in memory for this group was −1.84 SDs (95% CI: −2.28,
−1.39), which was −0.95 SDs (95% CI: −1.53, −0.38) faster
than the estimated rate for persons with the same degree of HI
who reported wearing a hearing aid. Notably, the global de-
cline in persons with moderate/severe HI who used hearing
aids (−0.97; Table 4) was only slightly greater than the cor-
responding decline in persons with normal hearing (−0.90;
Table 3).
For our longitudinal analysis, HI was not measured until
the end of follow-up for cognitive function. Therefore, one
possible interpretation of our findings is that cognitive de-
cline leads to HI (i.e., reverse causation), either from indirect
effects of cognitive impairment on the accuracy of hearing as-
sessment or from direct effects of neuropathology which con-
tributes to cognitive impairment (e.g., microvascular disease,
accumulation of amyloid β and τ protein) also affecting the
peripheral auditory system. However, pure tone audiometry
is considered a measure of the auditory periphery (not depen-
dent on higher-order auditory or cognitive processing (23)),
and valid hearing thresholds can be obtained even in partici-
pants with dementia (24). Neuropathology associated with
Table 2. Distributional Characteristics of Cognitive Test Scores by Domain, Atherosclerosis Risk in Communities Neurocognitive Study (n = 253),
1990–2013a





(n = 73) P Value
c
Moderate/Severe




Delayed Word Recall Test No. of words correctly recalled
1990–1992 (baseline) 7.1 (1.3) 6.9 (1.3) 7.0 (1.4) 7.5 (1.1) 0.013
2013 5.5 (1.7) 4.9 (1.8) 5.6 (1.5) 6.2 (1.7) <0.0001
Incidental learningd No. of symbols/digit-pairs recalled in 60
seconds
3.7 (2.4) 3.4 (2.2) 3.4 (2.4) 4.5 (2.5) 0.006
Logical memoryd No. of elements recalled in 2 trials 20.3 (6.9) 20.0 (7.1) 19.5 (7.0) 21.7 (6.6) 0.111
Language
Word Fluency Test No. of words generated in 3 trials
1990–1992 (baseline) 36.0 (11.1) 35.2 (11.7) 35.5 (10.9) 37.7 (10.6) 0.399
2013 33.3 (11.4) 31.3 (12.1) 34.0 (11.0) 34.8 (10.9) 0.117
Animal Naming Testd No. of animals named in 60 seconds 16.5 (4.5) 15.8 (4.7) 16.3 (4.4) 17.6 (4.3) 0.033
Boston Naming Testd No. of pictures identified 26.4 (3.8) 25.4 (5.0) 26.9 (2.4) 26.8 (3.4) 0.017
Processing speed/executive function
Digit Symbol Substitution Test No. of symbols completed in 90 seconds
1990–1992 (baseline) 51.4 (9.5) 48.9 (9.7) 51.7 (8.6) 53.8 (9.8) 0.007
2013 40.3 (9.8) 36.8 (9.2) 41.1 (9.3) 43.4 (9.9) 0.0001
Digit Span Backwards Testd No. of sequences recalled 5.8 (1.7) 5.7 (1.7) 6.0 (1.8) 5.7 (1.7) 0.576
Trail Making Test Part Ad,e,f Time to completion (seconds); lower
scores indicate better performance
36 (27–43) 34 (25–48) 38 (29–43) 36 (28–41) 0.616
Trail Making Test Part Bd,e,f Time to completion (seconds); lower
scores indicate better performance
106 (76–145) 111 (81–165) 107 (77–133) 95 (73–135) 0.122
Abbreviation: HI, hearing impairment.
a Values are expressed as mean (standard deviation) unless otherwise noted.
b HI was defined as none (≤25 dB)), mild (26–40 dB), or moderate/severe (>40 dB).
c P value from 1-way analysis of variance or a Kruskal-Wallis test comparing mean/median cognitive test scores across categories of HI.
d Measured only in 2013.
e Higher scores indicate better performance for all cognitive tests except the Trail Making Test Parts A and B, for which lower scores indicate better performance.
f Values are expressed as median and interquartile range (25th–75th percentiles).
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Alzheimer’s disease has also not been found in the peripheral
auditory pathways (25, 26), and we adjusted for multiple mid-
life and late-life cardiovascular risk factors in our analyses. Re-
gardless, we cannot rule out the possibility that the observed
association between HI and cognitive decline is due to an un-
measured factor that causes both conditions, although this lim-
itation is true for any observational epidemiologic study.
A number of mechanisms could account for the observed
association between HI and poorer cognitive functioning.
Persons with HI may perform more poorly on tests of cogni-
tive function because they are unable to hear test administra-
tors. However, although all cognitive tests require that the
participants hear the instructions, cognitive testing was rou-
tinely performed in a quiet room by technicians highly expe-
rienced in working with older adults, and we also observed
strong associations of HI with both auditory and nonauditory
cognitive tests.
HI has also been hypothesized to be a causal risk factor for
cognitive decline and dementia through several mechanisms
that are not mutually exclusive: increased social isolation and
loneliness, increased cognitive load, and changes in brain
structure. Social isolation is associated with physiological
changes, such as increases in systolic blood pressure and in-
creased glucocorticosteroid levels, which could in turn impact
brain structure, and several epidemiologic studies have demon-
strated an association between social isolation and accelerated
cognitive decline and dementia (27). In a recent cross-sectional
analysis of data from the National Health and Nutrition Exam-
ination Survey, HI was associated with increased odds (odds
ratio = 3.49, 95% CI: 1.91, 6.39) of social isolation in women
aged 60–69 years (28). Poor or impaired encoding by the co-
chlea may require extra cognitive processing effort, limiting
the effort available for encoding the content of speech into
memory. This increase in cognitive load due to HI has been
termed effortful listening (29, 30). Additionally, neuroimag-
ing studies have suggested that structural changes within the
brain may occur in response to HI, both cross-sectionally (31)
and longitudinally (32). For example, in 126 participants aged
56–86 years from theBaltimore Longitudinal StudyofAging,















































































Figure 1. Mean standardized cognitive test scores observed over time, by hearing impairment status, among participants in the Atherosclerosis
Risk in Communities Neurocognitive Study (n = 253), 1990–2013. A) DelayedWord Recall Test; B)Word Fluency Test; C) Digit Symbol Substitution
Test; D) global longitudinal composite score. Hearing impairment was measured in 2013.
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in the right temporal lobe (for participants with HI vs. partici-
pantswithout HI, difference in estimated average annual rate of
change = −0.29 cm3, 95% CI: −0.54, −0.04), as well as with
whole brain atrophy (estimated average difference in annual
rate of change associated with HI = 1.20 cm3, 95%CI:−2.17,
−0.22) (32).
Although estimates were imprecise because of the small
sample size, the estimated rate of 20-year memory decline
in persons with moderate/severe HI who did not report wear-
ing a hearing aid was large—about twice the average an-
nual rate of change estimated in nationally representative
studies of cognitive change in older adults (33, 34). However,
Table 3. Longitudinal, Multivariable-Adjusteda Estimates of Rates of Cognitive Change and Differences Between Estimated Rates of Cognitive
Change by Hearing Impairment Status,b Atherosclerosis Risk in Communities Neurocognitive Study (n = 253), 1990–2013
Cognitive Test and HI Category
Rate of Change
Years 1–5 (per 6 Years) Years 6–23 (per 6 Years) 20-Year Change
βc 95% CI P Value βc 95% CI P Value βd 95% CI P Value
Delayed Word Recall Test
HI category
Moderate/severe −0.19 −0.41, 0.04 0.107 −0.50 −0.61, −0.39 <0.0001 −1.35 −1.66, −1.05 <0.0001
Mild −0.22 −0.43, −0.01 0.038 −0.34 −0.44, −0.25 <0.0001 −1.02 −1.24, −0.80 <0.0001
None 0.03 −0.17, 0.24 0.741 −0.39 −0.51, −0.27 <0.0001 −0.88 −1.13, −0.64 <0.0001
Difference (mild HI vs. none) −0.25 −0.54, 0.04 0.086 0.05 −0.11, 0.20 0.521 −0.14 −0.47, 0.20 0.411
Difference (moderate/severe HI
vs. none)
−0.22 −0.56, 0.04 0.155 −0.11 −0.27, 0.05 0.186 −0.47 −0.86, −0.08 0.018
Word Fluency Test
HI category
Moderate/severe 0.06 −0.06, 0.19 0.310 −0.16 −0.23, −0.09 <0.0001 −0.31 −0.47, −0.15 <0.0001
Mild 0.16 0.03, 0.28 0.016 −0.11 −0.16, −0.06 <0.0001 −0.10 −0.23, 0.03 0.126
None 0.13 0.001, 0.26 0.048 −0.13 −0.19, −0.08 <0.0001 −0.17 −0.30, −0.03 0.015
Difference (mild HI vs. none) 0.02 −0.16, 0.21 0.802 0.02 −0.06, 0.10 0.614 0.07 −0.12, 0.26 0.463
Difference (moderate/severe HI
vs. none)
−0.07 −0.25, 0.11 0.451 −0.03 −0.11, 0.06 0.507 −0.14 −0.35, 0.07 0.198
Digit Symbol Substitution Test
HI category
Moderate/severe −0.21 −0.35, −0.08 0.002 −0.37 −0.43, −0.32 <0.0001 −1.09 −1.24, −0.93 <0.0001
Mild −0.19 −0.31, −0.07 0.002 −0.35 −0.41, −0.29 <0.0001 −1.01 −1.13, −0.88 <0.0001
None −0.19 −0.31, −0.07 0.002 −0.31 −0.36, −0.26 <0.0001 −0.92 −1.07, −0.77 <0.0001
Difference (mild HI vs. none) 0.001 −0.17, 0.17 0.987 −0.04 −0.12, 0.04 0.356 −0.09 −0.28, 0.11 0.377
Difference (moderate/severe HI
vs. none)
−0.02 −0.20, 0.16 0.801 −0.06 −0.14, 0.02 0.117 −0.17 −0.38, 0.05 0.124
Global longitudinal composite score
HI category
Moderate/severe −0.16 −0.30, −0.01 0.031 −0.45 −0.51, −0.38 <0.0001 −1.20 −1.38, −1.02 <0.0001
Mild −0.12 −0.24, 0.01 0.060 −0.37 −0.43, −0.30 <0.0001 −0.97 −1.11, −0.83 <0.0001
None −0.02 −0.13, 0.10 0.793 −0.38 −0.45, −0.31 <0.0001 −0.90 −1.08, −0.74 <0.0001
Difference (mild HI vs. none) −0.10 −0.27, 0.07 0.249 0.02 −0.08, 0.11 0.746 −0.06 −0.28, 0.15 0.570
Difference (moderate/severe HI
vs. none)
−0.14 −0.33, 0.04 0.133 −0.06 −0.16, 0.03 0.176 −0.29 −0.54, −0.05 0.019
Abbreviations: CI, confidence interval; HI, hearing impairment.
a Adjusted for age (years), age2 (years2), sex, education (high school or less vs. more than high school), smoking status (ever smoking vs. never
smoking), diabetes (fasting blood glucose concentration ≥126 mg/dL or participant self-report and medication use for diabetes), hypertension
(diastolic blood pressure ≥90 mm Hg, systolic blood pressure ≥140 mm Hg, or use of hypertensive medication), and Wide Range Achievement
Test score.
b HI was measured in 2013 and was defined as none (≤25 dB)), mild (26–40 dB), or moderate/severe (>40 dB). Numbers of participants with no
HI, mild HI, and moderate/severe HI were 73, 95, and 85, respectively.
c Estimate was scaled to 6 years so that the interpretation is the estimated rate of cognitive change per 6 years.
d Estimate combines rates of change before and after year 6 to give an overall estimate of the rate of cognitive change over 20 years.
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residual confounding may still have affected the longitudinal
differences we observed in rates of cognitive decline between
hearing aid users and nonusers. Nonusers in our sample had
more comorbidity (hypertension, diabetes) at a younger age
than did persons with the same amount of HI who reported
wearing a hearing aid. Given that hearing aids are not cur-
rently covered by Medicare and the average cost of a pair
of hearing aids is more than $2,000, hearing aid use could
also be a marker of better socioeconomic status and education
and therefore increased access to health care and/or a more
healthy lifestyle. However, education is not associated with
cognitive decline in this cohort (16), and other stable socio-
economic characteristics seem unlikely to influence measures
of change in cognition. Data on other key variables (e.g.,
duration of hearing aid use, adequacy of hearing aid fitting
and rehabilitation) that would affect the success of hearing
loss treatment and affect any observed association were also not
accounted for in our analyses. Nevertheless, althoughwe cannot
determine causality from this study, the slower rate of estimated
decline in hearing aid users as compared with nonusers is in-
triguing and should be the focus of further study.
Investigators in 2 previous studies of older adults reported
an association between HI and poorer performance on the
DSST. Cross-sectionally, HI was associated with a DSST
score difference of−1.5 points (95%CI:−2.9,−0.23) among
605 men and women in the National Health and Nutri-
tion Examination Survey (1). In a longitudinal analysis of
1,984 older adults (mean age = 77.4 years) from the Health,
Aging, and Body Composition Study, HI was associated with
faster rates of decline on the Modified Mini-Mental State Ex-
amination (P = 0.004)—a test of global function—and on the
DSST (P = 0.02) over 6 years of follow-up (3). In our study,
we observed faster rates of decline on the Delayed Word Re-
call Test—a word list learning task—and in global function,
but not on the DSST. In a recent analysis of the Baltimore
Longitudinal Study of Aging cohort, Lin et al. (2) reported
cross-sectional associations between HI and poorer cognitive














































































Moderate or severe (>40 dB)
Figure 2. Multivariable-adjusted estimates of mean standardized cognitive test scores over time, by hearing impairment status, Atherosclerosis
Risk in Communities Neurocognitive Study (n = 253), 1990–2013. A) DelayedWord Recall Test; B)Word Fluency Test; C) Digit Symbol Substitution
Test; D) global longitudinal composite score. Estimates were adjusted for age (years), age2 (years2), sex, education (high school or less vs. more
than high school), smoking status (ever smoking vs. never smoking), diabetes (fasting blood glucose concentration ≥126 mg/dL or participant self-
report and medication use for diabetes), hypertension (diastolic blood pressure ≥90 mm Hg, systolic blood pressure ≥140 mm Hg, or use of hyper-
tensive medication), and Wide Range Achievement Test score. Hearing impairment was measured in 2013.
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Cued Selective Reminding Test), executive function (Stroop
Test), and global function (Mini-Mental State Examination).
They reported no association with 2 tests of language (Animal
and Category Fluency) and with the Trail Making Test Parts A
and B, which is similar to our results. Previous studies have
also shown an association between HI and incident dementia.
In 1,057 men from the Caerphilly Prospective Study, audio-
metric HI was associated with increased odds of incident de-
mentia over 17 years of follow-up (odds ratio = 2.67, 95% CI:
1.38, 5.18) (35), and in 639 participants aged 36–90 years in
the Baltimore Longitudinal Study of Aging, baseline HI was
associated with increased risk of all-cause dementia over ap-
proximately 12 years of follow-up (per 10-dB loss, hazard
ratio = 1.27, 95% CI: 1.06, 1.50) (36). Our study adds to the
literature on HI and cognition in older adults through the inclu-
sion of multiple tests to measure several cognitive domains,
and it adds to the small but growing body of literature on HI
and domain-specific cognitive function.
Our results are limited in their generalizability, given that
our study consisted only of whites fromWashington County,
Maryland. Additionally, we did not have data on duration of
HI. Although our exposure was not measured until the end
of follow-up for cognitive function, longitudinal analyses of
cognitive change avoid the potentially strong cross-sectional
confounding effects of variables like education and other fac-
tors associated with social disadvantage (16).
In conclusion, this study documented amoderate association
between moderate/severe HI and memory performance, both at
the time of hearing testing and over the prior 20 years, in 253
white men and women from Washington County, Maryland.
This association was strongest among persons with moderate/
severe HI who reported not wearing a hearing aid. These find-
ings lend support to the hypothesis that HI may be a risk fac-
tor for cognitive decline in older adults and that hearing aid
use could possibly reduce that risk. HI is highly prevalent
among older adults, and although it is amenable to rehabili-
tative devices and interventions, these interventions remain
underutilized. Given the current lack of treatments for alter-
ing the natural history of cognitive decline and dementia, fur-
ther research is needed as to whether HI interventions could
reduce cognitive decline in older adults.
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Years 1–5 (per 6 Years) Years 6–23 (per 6 Years) 20-Year Change
βc 95% CI P Value βc 95% CI P Value βd 95% CI P Value
Delayed Word Recall Test
No hearing aid use −0.41 −0.74, −0.09 0.012 −0.61 −0.79, −0.43 <0.0001 −1.84 −2.28, −1.39 <0.0001
Hearing aid use 0.02 −0.30, 0.33 0.913 −0.39 −0.49, −0.28 <0.0001 −0.89 −1.25, −0.52 <0.0001
Difference (no use− use) −0.43 −0.88, 0.02 0.061 −0.22 −0.43, −0.01 0.037 −0.95 −1.53, −0.38 0.001
Word Fluency Test
No hearing aid use 0.04 −0.15, 0.22 0.694 −0.18 −0.29, −0.07 0.001 −0.38 −0.66, −0.10 0.008
Hearing aid use 0.09 −0.07, 0.25 0.275 −0.14 −0.22, −0.06 0.001 −0.24 −0.41, −0.07 0.007
Difference (no use− use) −0.05 −0.30, 0.19 0.676 −0.04 −0.17, 0.10 0.586 −0.14 −0.47, 0.19 0.404
Digit Symbol Substitution Test
No hearing aid use −0.29 −0.47, −0.10 0.002 −0.38 −0.47, −0.29 <0.0001 −1.18 −1.14, −0.93 <0.0001
Hearing aid use −0.15 −0.35, 0.05 0.139 −0.37 −0.44, −0.30 <0.0001 −1.00 −1.19, −0.82 <0.0001
Difference (no use− use) −0.14 −0.41, 0.13 0.319 −0.01 −0.13, 0.10 0.814 −0.17 −0.48, 0.13 0.274
Global longitudinal composite score
No hearing aid use −0.31 −0.52, −0.09 0.005 −0.49 −0.59, −0.39 <0.0001 −1.45 −1.70, −1.20 <0.0001
Hearing aid use −0.02 −0.21, 0.17 0.833 −0.41 −0.48, −0.33 <0.0001 −0.97 −1.21, −0.74 <0.0001
Difference (no use− use) −0.28 −0.57, 0.003 0.052 −0.08 −0.21, 0.04 0.184 −0.48 −0.83, −0.14 0.006
Abbreviation: CI, confidence interval.
a Adjusted for age (years), age2 (years2), sex, education (high school or less vs. more than high school), smoking status (ever smoking vs. never
smoking), diabetes (fasting blood glucose concentration ≥126 mg/dL or participant self-report and medication use for diabetes), hypertension
(diastolic blood pressure ≥90 mm Hg, systolic blood pressure ≥140 mm Hg, or use of hypertensive medication), and Wide Range Achievement
Test score.
b Hearing aid usewas measured in 2013 and was defined as self-reported use of a hearing aid in either ear during the previous month. Numbers
of participants who reported using a hearing aid and not using a hearing aid were 43 and 42, respectively.
c Estimate was scaled to 6 years so that the interpretation is the estimated rate of cognitive change per 6 years.
d Estimate combines rates of change before and after year 6 to give an overall estimate of the rate of cognitive change over 20 years.
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